Target intelligence / Profile preview

Viral protein 2 (VP2) (VP2)

Target
VP2
Molecular classification
Viral structural protein, Capsid protein, Viroporin
01

Overview

The **VP2 protein** is a viral structural protein that forms part of the capsid in multiple virus families. In polyomaviruses, VP2 is a minor capsid protein located inside the viral shell and is essential for proper genome packaging and entry into host cells[1][5]. In IBDV, VP2 forms trimers that are key building blocks of the capsid, providing important immunogenic epitopes for neutralizing antibodies[2][4]. In BTV, VP2 is the principal determinant of serotype specificity and mediates attachment and penetration during infection, making it a major vaccine target[3]. In DWV, VP2 interacts with host proteins (e.g., snapin), potentially influencing viral assembly and neuropathogenesis[7]. Across viruses, VP2's surface loops display sequence variability, influencing immune recognition and epitope diversity[6][4][8]. Direct drug targeting of VP2 is uncommon, but its antigenic properties make it a focus for vaccine development and serological assays. If VP2 is referenced without specifying virus type, additional characterization should be provided, as VP2 is a conserved nomenclature for various unrelated viral proteins. Each VP2 fulfills parallel roles in viral structure and function, with some species-specific molecular and immunological features.

Other names
Minor capsid protein VP2Structural protein VP2JC virus VP2IBDV VP2BTV VP2DWV VP2Rotavirus VP2
02

Mechanism of action

Neutralizing antibodies block viral entry by binding VP2 and preventing receptor interaction (e.g., BTV). VP2–host protein interactions influence virus assembly (e.g., snapin—DWV).

03

Biological functions

Viral entry facilitation (endoplasmic reticulum/nuclear penetration)DNA/RNA bindingGenome packaging for encapsidationImmunogenicity/epitope presentationInduction of apoptosis
04

Disease associations

Infection (central to viral lifecycle)Immunopathology (PML for JC virus; immunosuppression-related disease)Apoptosis
05

Safety considerations

Vaccine immunogenicity (potential for cross-reactivity)Virus escape via VP2 mutation/epitope variation
06

Biomarkers

Anti-VP2 neutralizing antibody titers (vaccine research and efficacy monitoring)VP2 epitope mapping (subtype/serotype discrimination)

Beyond the preview

Go deeper on Viral protein 2 (VP2) (VP2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Viral protein 2 (VP2) (VP2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call